Health
Omada Health’s Enhanced GLP-1 Care Track Demonstrates Increased Medication Persistence and Weight Loss Outcomes at 12 and 24 Weeks
New GLP-1 analysis reveals that by addressing real-world barriers to persistence, Omada’s companion program can help sustain GLP-1 use, delivering on clinical trials' promisesSAN FRANCISCO, June 17, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, released new data1 demonstrating that Omada’s GLP-1 companion program significantly improved persistence rates for GLP-1 medications. Evidence suggests that persistence on a GLP-1 is associated with g
About this update from Omada Health, Inc.
[{"type":"image","alt":"Omada Health, Inc.","displaySize":"","headline":null,"caption":"Omada Health, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":70,"url":"https://media.zenfs.com/en/globenewswire.com/c16cfad848d897c3a884329d0ddf5bfe"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vuZFZvLWZoBn6DNdLsNbgg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/c16cfad848d897c3a884329d0ddf5bfe","width":300,"height":70}},"lazy":false},{"type":"text","content":"New GLP-1 analysis reveals that by addressing real-world barriers to persistence, Omada’s companion program can help sustain GLP-1 use, delivering on clinical trials' promises","length":179,"tagName":"p"},{"type":"text","content":"SAN FRANCISCO, June 17, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, released new data1 demonstrating that Omada’s GLP-1 companion program significantly improved persistence rates for GLP-1 medications. Evidence suggests that persistence on a GLP-1 is associated with greater weight loss.2 Omada's analysis found that those who persisted with their GLP-1 medication achieved weight loss results similar to what has been found in controlled research settings.1","length":524,"tagName":"p"},{"type":"text","content":"Despite a growing body of evidence supporting vast clinical benefits of GLP-1s,3 while results vary widely, one study showed that one-third of people stopped taking their GLP-1 in the first month, and less than half stayed on for more than 12 weeks.4 These data suggest that in the real world, factors like non-persistent medication use mean that many who use GLP-1s for weight management may not see the results reflected in clinical trials.","length":442,"tagName":"p"},{"type":"text","content":"“While published literature illustrates the incredible potential of GLP-1s, these outcomes are generally limited to those who consistently use their medication long enough to see benefit. In the real world many patients do not receive the necessary support for this to be a reality,” said Sarah Linke, PhD, MPH, Senior Director, Clinical & Translational Research, Omada Health. “Omada's GLP-1 companion program helps individuals maintain their medication regimen and, in this analysis, helped members achieve clinical trial...